Axisgroup
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Single Cell Analysis Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Đã xuất bản: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The growth of the single cell analysis market is attributed to the technological advancements in single cell analysis products, increasing investments in cancer research, and rising biotechnology and biopharmaceutical industries in recent years.
Cancer is one of the major causes of deaths across the world, and there were 8.8 million victims in 2015, accounting for nearly one in six deaths. The disease has witnessed significant growth in the past few decades and is expected to rise rapidly over the forecast period. According to the World Health Organization (WHO), 10.9 million new cases of cancer were identified in 2002, which grew substantially over the next decade to approximately 14.1 million in 2012. An estimated 30% growth was observed over the decade. Moreover, WHO estimated the growth to increasing to 70% over the next two decades, worldwide. Circulating tumor cells are gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. In such cases, single-cell sequencing analysis has found its application in search of better diagnostic and prognostic biomarkers. In recent years, multiple technologies for enrichment, isolation, as well as molecular and functional analysis of circulating tumor cells have been developed, such as single cell analysis. In 2014, the Clinical Research Infrastructure Initiative brought together several funding organizations, such as the Welcome Trust and Cancer Research UK, in partnership, led by the Medical Research Council (MRC), in order to invest over GBP 230 million for single-cell genomics for cancer studies.
In clinical diagnostics, single cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. This is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research is considered as one of the major driving factors for the market over the forecast period.
Scope of the Report
As per the scope of this report, single cell analysis refers to the study of individual cells isolated from tissues in multicellular organisms. Study of living cells can increase the understanding of the interconnecting molecular events that are continually taking place within each cell.
Key Market Trends
Immunology Research Application is Expected to Grow with High CAGR During the Forecast Period
The cancer segment held the maximum share in 2018, owing to a high prevalence of cancer, initiatives for early detection, and increasing awareness regarding commercially available cancer diagnostics.
Immunology studies to aid in the early detection of therapeutic complications and increases the efficiency of the treatment. Furthermore, invasion of metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of immunology research segment.
North America Region Holds the Largest Market Share of Single Cell Analysis Market Market Currently and is Believed to Follow the Same Trend over the Forecast Period
The large share of the North American single cell analysis market is attributed to factors, such as increasing collaborations among prominent players, technological advancements, and expanding biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single cell analysis market in the region. For example, in 2015, the Precision Medicine Initiative was introduced to revolutionize the treatment of chronic diseases, including cancer.
The Asia-Pacific market is expected to witness the fastest growth during the forecast period, which is attributed to numerous government initiatives undertaken to improve healthcare infrastructure, availability of skilled professionals to operate advanced analytical instruments, and rising healthcare expenditure.
Competitive Landscape
The single cell analysis market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, Illumina Inc. and Bio-Rad Laboratories Inc. entered into a strategic collaboration in 2016, to co-develop comprehensive solution for single cell genomics
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Single Cell Analysis Products
4.2.2 Increasing Investments in Cancer Research
4.2.3 Rising Biotechnology and Biopharmaceutical Industries
4.3 Market Restraints
4.3.1 High Cost of Single Cell Analysis Instruments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cell Type
5.1.1 Human
5.1.2 Animal
5.1.3 Microbial
5.2 By Technique
5.2.1 Flow Cytometry
5.2.2 Next generation Sequencing
5.2.3 Polymerase Chain Reaction (PCR)
5.2.4 Microscopy
5.2.5 Mass Spectrometry
5.2.6 Other Techniques
5.3 By Application
5.3.1 Research Applications
5.3.1.1 Cancer Research
5.3.1.2 Immunology Research
5.3.1.3 Neurology Research
5.3.1.4 Stem Cell Research
5.3.1.5 Other Research Applications
5.3.2 Medical Application
5.3.2.1 Non-invasive Prenatal Diagnosis
5.3.2.2 In Vitro Fertilization
5.3.2.3 Circulating Tumor Cell Detection
5.4 By End User
5.4.1 Academic and Research Laboratories
5.4.2 Biotechnology and Pharmaceutical Companies
5.4.3 Hospital and Diagnostic Laboratories
5.5 Geography
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 UK
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Beckman Coulter Inc.
6.1.3 Becton, Dickinson, and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Fluidigm Corporation
6.1.6 GE Healthcare
6.1.7 Illumina Inc.
6.1.8 Merck KGaA
6.1.9 Qiagen NV
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Cell Type
Human
Animal
Microbial
By Technique
Flow Cytometry
Next generation Sequencing
Polymerase Chain Reaction (PCR)
Microscopy
Mass Spectrometry
Other Techniques
By Application
Research Applications
Cancer Research
Immunology Research
Neurology Research
Stem Cell Research
Other Research Applications
Medical Application
Non-invasive Prenatal Diagnosis
In Vitro Fertilization
Circulating Tumor Cell Detection
By End User
Academic and Research Laboratories
Biotechnology and Pharmaceutical Companies
Hospital and Diagnostic Laboratories
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Medical Laser Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Unknown |
| Unknown | Đã xuất bản: Unknown |
- Healthcare
- Mordor Intelligence
- pages
- Published:
Market Overview
The growth of the medical laser market is attributed to the rising preference for minimally invasive procedures, increasing incidences of eye disorders, and an increase in the number of cosmetic procedures.
The rising demand for surgeries with faster recovery, fewer post-surgery infections, less pain, reduced scarring, better control on bleeding, and increased accuracy are anticipated to boost the demand for various endoscopy devices. Technological advances in surgical techniques and enhancement in equipment handling have transformed surgical procedures, including the introduction of minimally invasive surgeries.
These procedures usually provide equivalent outcomes to traditional open surgery, along with offering significant benefits, such as less major bleeding, fewer post-op infections, fewer complications, shorter length of stay, quicker return to normal activities, less scarring, and comparable/lower cost, among other such benefits. As a result, these procedures have become more popular in recent times. Aging patients are fragile, and thus, the use of minimally invasive devices (while performing surgeries) becomes important. Hence, the increase in the prevalence of geriatric population is also driving the market.
Globally, there is an increased demand for cosmetic surgery procedures, which include surgical and non-surgical procedures that improve the appearance by reshaping and enhancing the body structure. For instance, as per a report published by the American Society of Plastic Surgeons in 2016, around 1.8 million cosmetic surgical procedures and 15.5 million cosmetic minimally invasive procedures were performed. This high adoption of medical lasers in the area of cosmetic surgery is also expected to propel the growth of the medical laser market.
Scope of the Report
As per the scope of this report, medical lasers are medical devices that are used for the treatment of various diseases and tissue removal, which helps in medical diagnosis, treatments, and therapies.
Key Market Trends
Semiconductor is Expected to Hold the Largest Revenue in the Products Segment
The semiconductor segment held a maximum share in 2018, as these semiconductors are widely used in aesthetic procedures and photodynamic treatment. Furthermore, semiconductor laser systems offer the deepest penetration levels and superior melanin absorption. These unique characteristics make the semiconductor laser the most suitable technology for laser hair removal, hence enabling safe and effective treatment of all skin and hair types in all body areas.
North America Region Holds the Largest Market Share of the Medical Laser Market Market Currently and is Believed to Follow the Same Trend Over the Forecast Period
The North American medical laser market dominated the global market and is estimated to show a similar trend during the forecast period. The increasing preference for cosmetic procedures and high adoption rate of novel technologies are the primary factors behind large market size.
Asia-Pacific is expected to grow at a rapid pace over the forecast period, owing to the increasing healthcare expenditure, rising awareness, and trend of medical tourism in the developing economies of the region.
Competitive Landscape
The medical laser market consists of several major players, including Bausch & Lomb Incorporated, Koninklijke Philips NV, and IRIDEX Corporation, among many others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, in February 2018, Lumenis launched Pico Fractional, a photoacoustic fractional laser system for skin resurfacing procedure.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Preference for Minimally Invasive Procedures
4.2.2 Increasing Incidences of Eye Disorders
4.2.3 Increase in the Number of Cosmetic Procedures
4.3 Market Restraints
4.3.1 High Installation Costs
4.3.2 Stringent Safety Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Solid State Laser Systems
5.1.1.1 Holmium Yttrium Aluminum Garnet Laser (Ho:Yag) Systems
5.1.1.2 Neodymium Yttrium Aluminum Garnet Laser (Nd:Yag) Systems
5.1.1.3 Potassium Titanyl Phosphate Laser Systems
5.1.1.4 Ruby Laser Systems
5.1.1.5 Other Solid State Laser Systems
5.1.2 Gas Laser Systems
5.1.2.1 CO2 Laser Systems
5.1.2.2 Argon Laser Systems
5.1.2.3 Krypton Laser Systems
5.1.2.4 Other Gas Laser Systems
5.1.3 Dye Laser Systems
5.1.4 Semiconductor Laser Systems
5.2 By Application
5.2.1 Ophthalmology
5.2.2 Dermatology
5.2.3 Gynecology
5.2.4 Dentistry
5.2.5 Urology
5.2.6 Cardiovascular
5.2.7 Cosmetics
5.2.8 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch & Lomb Incorporated.
6.1.2 Koninklijke Philips NV
6.1.3 IRIDEX Corporation
6.1.4 Biolase Inc.
6.1.5 Syneron-Candela
6.1.6 Lumenis Ltd
6.1.7 Alcon Laboratories Inc.
6.1.8 Cutera Inc.
6.1.9 American Medical Systems
6.1.10 PhotoMedex Inc.
6.1.11 Biolitec AG
6.1.12 AngioDynamics Corp.
6.1.13 Novadaq Technologies Inc.
6.1.14 Coherent Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Solid State Laser Systems
Holmium Yttrium Aluminum Garnet Laser (Ho:Yag) Systems
Neodymium Yttrium Aluminum Garnet Laser (Nd:Yag) Systems
Potassium Titanyl Phosphate Laser Systems
Ruby Laser Systems
Other Solid State Laser Systems
Gas Laser Systems
CO2 Laser Systems
Argon Laser Systems
Krypton Laser Systems
Other Gas Laser Systems
Dye Laser Systems
Semiconductor Laser Systems
By Application
Ophthalmology
Dermatology
Gynecology
Dentistry
Urology
Cardiovascular
Cosmetics
Other Applications
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Microbiology Testing Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Đã xuất bản: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The propelling factors for the growth of the microbiology testing market include technological advancements in microbiology testing, rising incidences of infectious diseases and outbreak of epidemics, growing healthcare expenditure, and rising private-public funding for research on infectious diseases.
Infectious diseases, such as HIV, human papilloma virus (HPV), and hepatitis B and C, are some forms of STDs that are severe and fatal, and thus the increasing incidences of such diseases are increasing the demand for the microbiology testing market. Increasing healthcare expenditure and the presence of better medical infrastructures, such as hospitals and clinical labs, are some other drivers augmenting the growth of the microbiology testing market.
Rapid growth observed in the geriatric population, increasing number of clinical researches in the field of clinical microbiology, rising incidences of infectious diseases, and increased funding, research grants, and public-private investments are some of the factors that are driving the microbiology testing market.
Rapid technological advancements are also being witnessed across the world that are anticipated to drive the microbiology testing market in the upcoming years. There are emerging economies, such as India and China, which may offer new growth opportunities for the microbiology testing market over the forecast period.
Scope of the Report
As per the scope of the report, microbial testing is an analytical technique that is utilized to determine the number of microorganisms in food, beverages, biological samples, and environmental samples. The microbial testing technique employs chemical, biological, biochemical, or molecular methods to identify and quantify the microbes. It is one of the important processes carried out in medical, healthcare, and food industries for the prevention of future product damages.
Key Market Trends
Diagnostic Holds the Largest Revenue Share in the Applications and is Expected to do Same
The diagnostics segment is expected to account for the largest share of the microbiology testing market. Some of the key factors driving the growth of this segment are the increasing prevalence of infectious diseases, improving healthcare expenditure, and technological advancements.
The pharmaceutical application segment is also expected to dominate due to the presence of well-established and globally accepted regulations, which govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing processes.
Europe Holds the Fastest Growth and is Expected to Follow the Same Trend Over the Forecast Period
The European region is expected to show the fastest growth for microbiology testing and is anticipated to contribute notably toward the microbiology testing market over the forecast period. These can be attributed to the presence of advanced healthcare infrastructure in the region, along with various technological advancements witnessed in this region’s healthcare industry.
However, Asia-Pacific is also expected to grow in the upcoming future, due to the expanding R&D and innovative microbiology testing procedures and the increasing number of hospitals and testing laboratories.
Competitive Landscape
The microbiology testing market has witnessed new product launches, mergers and acquisitions, partnerships, joint ventures, and strategies adopted by the major players to gain competitive advantage. The companies are also introducing advanced microbiological automated systems that have high throughputs and are less time-consuming.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Microbiology Testing
4.2.2 Rising Incidences of Infectious Diseases and Outbreak of Epidemics
4.2.3 Growing Healthcare Expenditure
4.2.4 Rising Private-Public Funding for Research on Infectious Diseases
4.3 Market Restraints
4.3.1 Laboratory Reimbursement Issues
4.3.2 High Cost of Microbiology Instruments
4.4 Porters Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Pharmaceutical Application
5.1.2 Diagnostic Application
5.1.3 Food and Beverage Testing Application
5.1.4 Environmental Application
5.1.5 Cosmetic Application
5.1.6 Other Applications
5.2 By Product
5.2.1 Equipment
5.2.2 Reagent
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio-Rad Laboratories Inc.
6.1.2 Abbott Laboratories
6.1.3 Becton Dickinson and Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Bruker Corporation
6.1.6 Hologic Corporation
6.1.7 Cepheid Inc.
6.1.8 Biomerieux SA
6.1.9 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Application
Pharmaceutical Application
Diagnostic Application
Food and Beverage Testing Application
Environmental Application
Cosmetic Application
Other Applications
By Product
Equipment
Reagent
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Retinoblastoma Treatment Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Đã xuất bản: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 13-06-2019
Market Overview
Global Retinoblastoma Treatment market was valued at USD 2297.13 million in 2018, and is estimated to be valued at USD 3001.78 million in 2024, witnessing a CAGR of 4.56%. certain factors that are driving the market growth include remission and the chance of recurrence, and increasing public awareness.
Recurrent retinoblastoma occurs, when cancer comes back after it has been treated and diagnosed. Both extraocular and intraocular retinoblastoma might have probable chances of remittance.
Generally, the likelihood of relapse and formation of secondary tumors increases with the genetic nature of the disease. Patients with non-hereditary or sporadic retinoblastoma are not as susceptible to relapse, as hereditary ones. Although, the cure rate for retinoblastoma is quite high, the exact cure rate is dependent on the extent of the disease and chances of recurrence. The increasing number of treatment procedures drive the retinoblastoma treatment market.
In addition, improving awareness about retinoblastoma is a worthwhile goal, and any eye complaint merits careful attention from all nursing and medical personnel. Improving awareness regarding retinoblastoma is especially important in developing countries, as the incidences of eye cancer are increasing, and many children die undiagnosed or have advanced disease at presentation, due to delay in referral to an oncology centre. Retinoblastoma educational and public awareness campaigns have been shown to increase referrals, decrease rates of advanced disease, and improve outcomes in low and middle-income countries.
However, side effects of retinoblastoma surgery, radiation therapy to the head and certain chemotherapy drugs, such as cisplatin and carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when they are given to very young children. The other eye problems include difficulty in judging distance between objects and difficulty seeing to the side (peripheral vision). Eye problems can also lead to changes in balance.
Scope of the Report
Retinoblastoma is the most common cancer among children, which starts in the retina. It generally develops before the age of 5. One out of three children with retinoblastoma develops cancer in both eyes. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called cat’s eye reflex or leukocoria.
Key Market Trends
Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment
In the Retinoblastoma type segment of the Retinoblastoma treatment market, the non-hereditary retinoblastoma (NHR) is expected to have the largest market size and is likely to witness a CAGR of 3.82% in the forecast period.
Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.
The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 – 18,000 live births).
The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.
Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period
Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.
According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.
Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.
Competitive Landscape
The Retinoblastoma Treatment market is moderately competitive and consists of a considerable number of major players. Companies like B Baxter International Inc., GlaxoSmithKline, Pfizer Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, Merck & Co., Cadila Pharmaceuticals, and Teva Pharmaceutical, among others, are expected to hold the substantial market share in the Retinoblastoma Treatment market.
Various developments have recently been taking place in the market. For example, in June 2018, GSK completed the Consumer Healthcare buyout of Novartis.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Remission and the Chance of Recurrence
4.2.2 Increasing Public Awareness
4.3 Market Restraints
4.3.1 Small Patient Pool
4.3.2 Side Effects of Retinoblastoma Surgery
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Surgery
5.1.2 Radiation therapy
5.1.3 Laser Therapy (Photocoagulation)
5.1.4 Cryotherapy
5.1.5 Thermotherapy
5.1.6 Chemotherapy
5.1.6.1 Carboplatin
5.1.6.2 Cisplatin
5.1.6.3 Vincristine
5.1.6.4 Etoposide
5.1.6.5 Cyclophosphamide
5.1.6.6 Topotecan
5.1.6.7 Doxorubicin
5.1.6.8 Cyclosporine
5.1.6.9 Melphalan
5.1.7 Opthalmic Artery Infusion Chemotherapy
5.1.8 High-dose Chemotherapy and Stem Cell Transplant
5.2 By Type of Retinoblastoma
5.2.1 Non-hereditary Retinoblastoma
5.2.2 Hereditary Retinoblastoma
5.3 By Type of Staging
5.3.1 Intraocular Retinoblastoma
5.3.2 Extraocular Retinoblastoma
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Cadila Pharmaceuticals
6.1.4 GlaxoSmithKline plc
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Surgery
Radiation therapy
Laser Therapy (Photocoagulation)
Cryotherapy
Thermotherapy
Chemotherapy
Carboplatin
Cisplatin
Vincristine
Etoposide
Cyclophosphamide
Topotecan
Doxorubicin
Cyclosporine
Melphalan
Opthalmic Artery Infusion Chemotherapy
High-dose Chemotherapy and Stem Cell Transplant
By Type of Retinoblastoma
Non-hereditary Retinoblastoma
Hereditary Retinoblastoma
By Type of Staging
Intraocular Retinoblastoma
Extraocular Retinoblastoma
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Spain In-Vitro Diagnostics Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 62 pages | Đã xuất bản: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 62 pages
- Published: 13-06-2019
Market Overview
The key factors propelling the growth of the Spanish in vitro diagnostics market is the high prevalence of chronic diseases, increasing use of point-of-care (POC) diagnostics, and advanced technologies.
The increasing incidences of chronic and infectious diseases and a rapidly evolving healthcare environment are expected to drive the Spanish in vitro diagnostics market in the years to come. They account for the majority of hospital admissions and prescriptions filling. They are also a major reason for physician visits. These diseases account for the vast majority of healthcare spending. Hence, the high prevalence of chronic diseases in the country is the primary factor responsible for the growth of the IVD market in Spain.
Owing to the ease of use and ability to provide instant results, combined with ease of procurement, the use of POC diagnostics in Spain is increasing rapidly, and this, in turn, is promoting the growth of the IVD market in the country. POC technologies form an influential driver for the market.
In addition, rapid advancements in the technology and increasing adoption toward novel technologies are the other factors contributing to the growth of the IVD market in the country.
Scope of the Report
As per the scope of the report, in vitro diagnostics involves the medical devices and consumables that are utilized to perform in vitro tests on various biological samples. These tests are done on samples, such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to cure, treat, or prevent diseases.
Key Market Trends
POC Diagnostics Holds the Largest Share in the by Technique Segment
The POC diagnostics segment is increasing due to factors, such as the rising prevalence of chronic and infectious diseases, private investments, and venture capital activities supporting R&D of novel products, which are expected to boost the market growth. In addition, rapid advancements in POC technology and increasing adoption toward novel technologies are the other factors contributing to the growth of the IVD market in the country.
Competitive Landscape
The companies are found focusing on increasing technological advancements in order to address customer needs, like fully automated systems that save manual processes and consumables. Manual processes also provide fast and accurate results. In addition, all the major IVD companies have launched new products for strengthening their diagnostic capabilities.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Unclear Reimbursement Policies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technique
5.1.1 Immunochemistry
5.1.2 POC Diagnostics
5.1.3 Molecular Diagnostics
5.1.4 Hematology
5.1.5 Tissue Diagnostics
5.1.6 Microbiology
5.1.7 Self-blood Glucose Monitoring
5.1.8 Other Techniques
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Data Management System
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 HIV/AIDS
5.4.9 Other Applications
5.5 By End Users
5.5.1 Laboratory
5.5.2 Hospital
5.5.3 Academia
5.5.4 POC Testing
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 bioMerieux SA
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthcare GmbH
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technique
Immunochemistry
POC Diagnostics
Molecular Diagnostics
Hematology
Tissue Diagnostics
Microbiology
Self-blood Glucose Monitoring
Other Techniques
By Product
Instrument
Reagent
Data Management System
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
HIV/AIDS
Other Applications
By End Users
Laboratory
Hospital
Academia
POC Testing
Insulin Infusion Pumps Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Đã xuất bản: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The global insulin infusion pump market is set to witness a CAGR of 7.51% during the forecast period. Insulin infusion pumps work as an alternative to the traditional system of daily injections or an insulin pen.
Insulin infusion pumps reduce the large swings in blood glucose level, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps.
This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.
The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like the integration of continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm that automatically delivers the insulin, after analyzing the blood glucose reading
Scope of the Report
The insulin market is segmented into the device, infusion set, and reservoir. The report is also segmented into five regions: North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America.
Key Market Trends
The Insulin Pump Market is Growing with the CAGR of 7% in the Forecast Period
Owing to the rising rate of obesity, growing genetic factors for type 2 diabetes, and the increasing number of type 1 diabetes patients, it is likely that the insulin infusion pump market will continue to grow.
Insulin pump use is high among the type 1 population. It is also growing in type 2 patients. The ratio of children to adult, or type 1 to type 2, patient’s usage of insulin pumps varies across countries.
North America Holds the Highest Market Share
North America holds the highest market share in the insulin pump market and is also expected to grow with the highest CAGR, of 9.05% in the forecast period, because of the favorable reimbursement policy. Although the pump and its supplies (tubing, insulin cartridges, and infusion sets) continue to be expensive, insurance coverage has improved considerably over the years.
Competitive Landscape
Animas had to exit the insulin pump market, as the company has admitted that rising competition was the reason for them to leave the market.
Medtronic is the market leader and is expected to maintain its position during the forecast period.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product (Value and Volume 2012-2024)
5.1.1 Insulin Pumps
5.1.2 Infusion Sets
5.1.3 Reservoirs
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Insulin Pump Devices
5.2.1.1.2 By Infusion Sets
5.2.1.1.3 By Reservoirs
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Insulin Pump Devices
5.2.1.2.2 By Infusion Sets
5.2.1.2.3 By Reservoirs
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Insulin Pump Devices
5.2.1.3.2 By Infusion Sets
5.2.1.3.3 By Reservoirs
5.2.2 Asia-Pacific
5.2.2.1 Japan (Value and Volume 2012-2024)
5.2.2.1.1 By Insulin Pump Devices
5.2.2.1.2 By Infusion Sets
5.2.2.1.3 By Reservoirs
5.2.2.2 South Korea (Value and Volume 2012-2024)
5.2.2.2.1 By Insulin Pump Devices
5.2.2.2.2 By Infusion Sets
5.2.2.2.3 By Reservoirs
5.2.2.3 China (Value and Volume 2012-2024)
5.2.2.3.1 By Insulin Pump Devices
5.2.2.3.2 By Infusion Sets
5.2.2.3.3 By Reservoirs
5.2.2.4 India (Value and Volume 2012-2024)
5.2.2.4.1 By Insulin Pump Devices
5.2.2.4.2 By Infusion Sets
5.2.2.4.3 By Reservoirs
5.2.2.5 Australia (Value and Volume 2012-2024)
5.2.2.5.1 By Insulin Pump Devices
5.2.2.5.2 By Infusion Sets
5.2.2.5.3 By Reservoirs
5.2.2.6 Vietnam (Value and Volume 2012-2024)
5.2.2.6.1 By Insulin Pump Devices
5.2.2.6.2 By Infusion Sets
5.2.2.6.3 By Reservoirs
5.2.2.7 Malaysia (Value and Volume 2012-2024)
5.2.2.7.1 By Insulin Pump Devices
5.2.2.7.2 By Infusion Sets
5.2.2.7.3 By Reservoirs
5.2.2.8 Indonesia (Value and Volume 2012-2024)
5.2.2.8.1 By Insulin Pump Devices
5.2.2.8.2 By Infusion Sets
5.2.2.8.3 By Reservoirs
5.2.2.9 Philippines (Value and Volume 2012-2024)
5.2.2.9.1 By Insulin Pump Devices
5.2.2.9.2 By Infusion Sets
5.2.2.9.3 By Reservoirs
5.2.2.10 Thailand (Value and Volume 2012-2024)
5.2.2.10.1 By Insulin Pump Devices
5.2.2.10.2 By Infusion Sets
5.2.2.10.3 By Reservoirs
5.2.2.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.2.11.1 By Insulin Pump Devices
5.2.2.11.2 By Infusion Sets
5.2.2.11.3 By Reservoirs
5.2.3 Europe
5.2.3.1 United Kingdom (Value and Volume 2012-2024)
5.2.3.1.1 By Insulin Pump Devices
5.2.3.1.2 By Infusion Sets
5.2.3.1.3 By Reservoirs
5.2.3.2 France (Value and Volume 2012-2024)
5.2.3.2.1 By Insulin Pump Devices
5.2.3.2.2 By Infusion Sets
5.2.3.2.3 By Reservoirs
5.2.3.3 Germany (Value and Volume 2012-2024)
5.2.3.3.1 By Insulin Pump Devices
5.2.3.3.2 By Infusion Sets
5.2.3.3.3 By Reservoirs
5.2.3.4 Italy (Value and Volume 2012-2024)
5.2.3.4.1 By Insulin Pump Devices
5.2.3.4.2 By Infusion Sets
5.2.3.4.3 By Reservoirs
5.2.3.5 Spain (Value and Volume 2012-2024)
5.2.3.5.1 By Insulin Pump Devices
5.2.3.5.2 By Infusion Sets
5.2.3.5.3 By Reservoirs
5.2.3.6 Russia (Value and Volume 2012-2024)
5.2.3.6.1 By Insulin Pump Devices
5.2.3.6.2 By Infusion Sets
5.2.3.6.3 By Reservoirs
5.2.3.7 Rest of Europe (Value and Volume 2012-2024)
5.2.3.7.1 By Insulin Pump Devices
5.2.3.7.2 By Infusion Sets
5.2.3.7.3 By Reservoirs
5.2.4 Latin America
5.2.4.1 Mexico (Value and Volume 2012-2024)
5.2.4.1.1 By Insulin Pump Devices
5.2.4.1.2 By Infusion Sets
5.2.4.1.3 By Reservoirs
5.2.4.2 Brazil (Value and Volume 2012-2024)
5.2.4.2.1 By Insulin Pump Devices
5.2.4.2.2 By Infusion Sets
5.2.4.2.3 By Reservoirs
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.4.3.1 By Insulin Pump Devices
5.2.4.3.2 By Infusion Sets
5.2.4.3.3 By Reservoirs
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Insulin Pump Devices
5.2.5.1.2 By Infusion Sets
5.2.5.1.3 By Reservoirs
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Insulin Pump Devices
5.2.5.2.2 By Infusion Sets
5.2.5.2.3 By Reservoirs
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Insulin Pump Devices
5.2.5.3.2 By Infusion Sets
5.2.5.3.3 By Reservoirs
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Insulin Pump Devices
5.2.5.4.2 By Infusion Sets
5.2.5.4.3 By Reservoirs
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Insulin Pump Devices
5.2.5.5.2 By Infusion Sets
5.2.5.5.3 By Reservoirs
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Insulin Pump Devices
5.2.5.6.2 By Infusion Sets
5.2.5.6.3 By Reservoirs
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Medtronic
7.1.2 Insulet
7.1.3 Roche
7.1.4 Animas
7.1.5 Tandem
7.1.6 Ypsomed
7.1.7 Cellnovo
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Animas
7.2.3 Medtronic
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product (Value and Volume 2012-2024)
Insulin Pumps
Infusion Sets
Reservoirs
Geography
North America
United States (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Canada (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of North America (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
South Korea (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
China (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
India (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Australia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Vietnam (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Malaysia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Indonesia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Philippines (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Thailand (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Europe
United Kingdom (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
France (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Germany (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Italy (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Spain (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Russia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Europe (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Latin America
Mexico (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Brazil (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Latin America (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Iran (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Egypt (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Oman (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
South Africa (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Insulin Pump Devices
By Infusion Sets
By Reservoirs